Arsenic trioxide
DB01169
Approved Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
10
Targets
0
Resistance Mutations
1
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
The mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells <i>in vitro</i>. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis.
Details
DrugBank ID
DB01169 ↗
Approval Date
2000-10-15
Molecular Weight
197.84 g/mol
Drug Class
Other
ATC Codes
L01XX27
Synonyms
Acide Arsenieux, Anhydride Arsenieux, Arsenic Blanc
PubChem
CID: 261004 ↗
ChEMBL
CHEMBL1200978 ↗
SMILES
O=[As]O[As]=O
ADMET Profile
Computing properties…
Drug References (DrugBank)